TUSTIN, CA, May 10, 2010 (MARKETWIRE via COMTEX News Network) -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing innovative monoclonal antibodies for the treatment of cancer and viral infections, today announced it will present at the Rodman & Renshaw Sixth Annual Global Investment Conference in London on Tuesday, May 18, 2010 at 10:40 am BST (5:40 am EDT). The conference will be held at the Grosvenor House Hotel in London, UK.

A live webcast of the company's presentation will be available in the Investors section of Peregrine's website at http://www.peregrineinc.com. A replay will be available on the Peregrine website and will be archived for 30 days.

For more information about this conference, please visit:

http://www.rodmanandrenshaw.com/conferences?id=44.

About Peregrine Pharmaceuticals Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative monoclonal antibodies in clinical trials for the treatment of cancer and serious viral infections. The company is pursuing three separate clinical programs in cancer and hepatitis C virus infection with its lead product candidates bavituximab and Cotara(R). Peregrine also has in-house cGMP manufacturing capabilities through its wholly owned subsidiary Avid Bioservices, Inc. (www.avidbio.com), which provides development and biomanufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at www.peregrineinc.com.

Contacts:
Investors
Amy Figueroa
Peregrine Pharmaceuticals
(800) 987-8256
info@peregrineinc.com

Media
Barbara Lindheim
BioCom Partners
(212) 918-4650

SOURCE: Peregrine Pharmaceuticals

mailto:info@peregrineinc.com

Copyright 2010 Marketwire, Inc., All rights reserved.

News Provided by COMTEX